Hanson Wade specializes in scientific research across a comprehensive range of distinctive R&D areas. We deliver insight and connections to facilitate safe and effective drug development for more personalized and targeted patient populations. It clinical momentum from Eli Lilly’s lipidated brain shuttle siRNAs, Alnylam Pharmaceuticals’ ALN-APP siRNA, Wave’s Phase 1b/2a positive SELECT-HD data, 170+ biotech and 30+ pharma active in the field, and a surge of novel approaches, the oligonucleotide field shows no signs of slowing down.